Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DFP00173 is a **potent and selective small molecule inhibitor of aquaporin-3 (AQP3)**, a membrane channel protein involved in water and glycerol transport. DFP00173 inhibits both mouse and human AQP3 with an IC50 of approximately 0.1–0.4 μM and shows minimal activity against the homologous aquaporin subtypes AQP7 and AQP9. By blocking AQP3, DFP00173 reduces glycerol and hydrogen peroxide permeability in vitro, affecting cell migration and potentially cytokine signaling. It has utility as a tool compound for research on aquaporin function and may inform strategies for targeting AQP3 in diseases such as breast cancer and for immunological modulation[1][2][3][4][5][6][7][9][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DFP00173.